Photodynamic Therapy for Actinic Keratoses

Dermatologic Clinics

Volumn 25, Issue 1, 2007, Pages 15-23

  Kalisiak, Michal S ^a   Rao, Jaggi ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; PHOTOSENSITIZING AGENT; PORPHYRIN; RETINOID;

ACTINIC KERATOSIS; APPLICATION SITE BURNING; APPLICATION SITE DISCOMFORT; APPLICATION SITE ERYTHEMA; BASAL CELL CARCINOMA; BLUE LIGHT; BOWEN DISEASE; CLINICAL TRIAL; CRYOSURGERY; CRYOTHERAPY; CURETTAGE; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HISTOPATHOLOGY; HUMAN; LIGHT EMITTING DIODE; MEDICAL DOCUMENTATION; MELANOMA; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PHYSICAL CHEMISTRY; PORPHYRIN METABOLISM; PRIORITY JOURNAL; RED LIGHT; REVIEW; RISK BENEFIT ANALYSIS; SKIN ABRASION; SKIN BIOPSY; SKIN DISEASE; TELANGIECTASIA; TISSUE SECTION;

AMINOLEVULINIC ACID; HUMANS; KERATOSIS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; ULTRAVIOLET RAYS;

EID: 33751170252     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2006.09.006     Document Type: Review

References (39)

1. Gupta A.K., Cooper E.A., Feldman S.R., et al. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis 70 2 Suppl (2002) 8-13
2. Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol 149 Suppl 66 (2003) 31-33
3. Glogau R.G. The risk of progression to invasive disease. J Am Acad Dermatol 42 1 Pt 2 (2000) 23-24
4. Kennedy J.C., Pottier R.H., and Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 6 1-2 (1990) 143-148
5. Gold M.H., and Nestor M.S. Current treatments of actinic keratosis. J Drugs Dermatol 5 2 Suppl (2006) 17-25
6. Cockerell C.J., and Wharton J.R. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol 4 4 (2005) 462-467
7. Davis D.A., Donahue J.P., Bost J.E., et al. The diagnostic concordance of actinic keratosis and squamous cell carcinoma. J Cutan Pathol 32 8 (2005) 546-551
8. Gold M.H. The evolving role of aminolevulinic acid hydrochloride with photodynamic therapy in photoaging. Cutis 69 6 Suppl (2002) 8-13
9. Goldman M.P. Photodynamic therapy (2005), Elsevier, Philadelphia
10. Angell-Petersen E., Sorensen R., Warloe T., et al. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 126 2 (2006) 265-271
11. Juzenas P., Juzeniene A., Kaalhus O., et al. Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo. Photochem Photobiol Sci 1 10 (2002) 745-748
12. Fotinos N., Campo M.A., Popowycz F., et al. 5-Aminolevulinic acid aerivatives in photomedicine: basics, application and perspectives. Photochem Photobiol 82 4 (2006) 994-1015
13. Goldman M.P., Weiss R.A., and Weiss M.A. Intense pulsed light as a nonablative approach to photoaging. Dermatol Surg 31 9 Pt 2 (2005) 1179-1187
14. Varma S., Wilson H., Kurwa H.A., et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 144 3 (2001) 567-574
15. Zelickson B., Counters J., Coles C., et al. Light patch: preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis. Dermatol Surg 31 3 (2005) 375-378
16. Wolf P., Rieger E., and Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?. J Am Acad Dermatol 28 1 (1993) 17-21
17. Morton C.A., Whitehurst C., Moore J.V., et al. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 143 4 (2000) 767-772
18. Calzavara-Pinton P.G. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 29 1 (1995) 53-57
19. Jeffes E.W., McCullough J.L., Weinstein G.D., et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol 133 6 (1997) 727-732
20. Fijan S., Honigsmann H., and Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 133 2 (1995) 282-288
21. Fink-Puches R., Hofer A., Smolle J., et al. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J Photochem Photobiol B 41 1-2 (1997) 145-151
22. Ericson M.B., Sandberg C., Stenquist B., et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 151 6 (2004) 1204-1212
23. Henderson B.W., Busch T.M., and Snyder J.W. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med 38 5 (2006) 489-493
24. Touma D., Yaar M., Whitehead S., et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 140 1 (2004) 33-40
25. Perotti C., Fukuda H., DiVenosa G., et al. Porphyrin synthesis from ALA derivatives for photodynamic therapy. In vitro and in vivo studies. Br J Cancer 90 8 (2004) 1660-1665
26. DUSA Pharmaceuticals. Levulan Kerastick (aminolevulinic acid HCl) for topical solution, 20%. Product Insert. 2004.
27. Szeimies R.M., Karrer S., Radakovic-Fijan S., et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 47 2 (2002) 258-262
28. Freeman M., Vinciullo C., Francis D., et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 14 2 (2003) 99-106
29. Pariser D.M., Lowe N.J., Stewart D.M., et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 48 2 (2003) 227-232
30. Piacquadio D.J., Chen D.M., Farber H.F., et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 140 1 (2004) 41-46
31. Tarstedt M., Rosdahl I., Berne B., et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derma Venereol 85 5 (2005) 424-428
32. Stockfleth E., Ulrich C., Meyer T., et al. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 160 (2002) 251-258
33. Dragieva G., Hafner J., Dummer R., et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 77 1 (2004) 115-121
34. Dragieva G., Prinz B.M., Hafner J., et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 151 1 (2004) 196-200
35. Sheil A.G., Disney A.P., Mathew T.H., et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 25 1 Pt 2 (1993) 1383-1384
36. de Graaf Y.G., Kennedy C., Wolterbeek R., et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 126 3 (2006) 569-574
37. Oseroff A. PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol 126 3 (2006) 542-544
38. Avram D.K., and Goldman M.P. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 3 1 Suppl (2004) S36-S39
39. Langan S.M., and Collins P. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol 154 1 (2006) 146-149